Clinical Scorecard: Patterns of Enteric Fever and the Rise of Extensively Drug-Resistant Typhoid in Pakistan: A Population-Based Analysis of Laboratory Data from 2017 to 2019

At a Glance

Key Highlights

• High prevalence of extensively drug-resistant (XDR) S. Typhi isolates (57%) with increasing cases from 2017 to 2019, especially in Sindh province.
• Most S. Typhi isolates resistant to first-line antibiotics including ampicillin (79.8%), chloramphenicol (80.8%), cefixime (64.6%), ciprofloxacin (66.4%), ceftriaxone (63.3%), and co-trimoxazole (80.2%).
• S. Paratyphi isolates largely remain susceptible to most antibiotics except high resistance to ciprofloxacin (85.9%). Both S. Typhi and S. Paratyphi remain susceptible to azithromycin, imipenem, and meropenem.

Guideline-Based Recommendations

Diagnosis

• Use blood culture confirmation for diagnosis of enteric fever.
• Employ standardized laboratory platforms (Bactec or Vitek) and CLSI guidelines for antimicrobial susceptibility testing.

Management

• Avoid first-line antibiotics with high resistance rates such as ampicillin, chloramphenicol, cefixime, ciprofloxacin, ceftriaxone, and co-trimoxazole for XDR typhoid.
• Consider azithromycin, imipenem, or meropenem for treatment of XDR S. Typhi infections.

Monitoring & Follow-up

• Implement continuous surveillance of antimicrobial resistance patterns using large laboratory networks.
• Monitor age-specific prevalence, focusing on children aged 5–14 years who have the highest proportion of MDR and XDR cases.

Risks

• Rising antimicrobial resistance threatens effective treatment of typhoid fever.
• Inadequate water, sanitation, and hygiene (WASH) conditions contribute to disease persistence and spread.

Patient & Prescribing Data

Children aged 2–14 years in Pakistan with blood culture–confirmed typhoid fever

High resistance to traditional first-line antibiotics necessitates use of azithromycin or carbapenems for XDR typhoid; S. Paratyphi remains largely susceptible except to ciprofloxacin.

Clinical Best Practices

• Leverage extensive laboratory networks for robust surveillance of typhoid epidemiology and resistance patterns.
• Use antimicrobial susceptibility testing to guide targeted antibiotic therapy.
• Prioritize vaccination and WASH improvements to reduce disease burden and resistance emergence.
• Focus clinical attention on pediatric populations with highest disease burden and resistance rates.

References

• Global typhoid burden decline data
• Surveillance for Enteric Fever in Asia Project (SEAP) Pakistan incidence data
• SEAP study on XDR typhoid in Pakistan
• Clinical Laboratory Standards Institute (CLSI) guidelines